Gonadotrophin Releasing Hormone Analogues for Ovarian Function Preservation in Young Females Undergoing Chemotherapy |
Bansal, Anshuma
(Radiation Oncology, Medical Education and Research)
Patel, Firuza Darius (Radiation Oncology, Medical Education and Research) Rai, Bhavana (Radiation Oncology, Medical Education and Research) Dhanireddy, Bhaswanth (Radiation Oncology, Medical Education and Research) Sharma, Suresh Chand (Radiation Oncology, Medical Education and Research) |
1 | Ortin TT, Shostak CA, Donaldson SS (1990). Gonadal status and reproductive function following treatment for Hodgkin's disease in childhood: the Stanford experience. Int J Radiat Oncol Biol Phys, 19, 873-80. DOI |
2 | Walshe J, Denduluri N, Swain S (2006). Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol, 24, 5769-79. DOI ScienceOn |
3 | Licciardi FL, Liu HC, Rosenwaks Z (1995). Day 3 estradiol serum concentrations as prognosticators of ovarian stimulation response and pregnancy outcome in patients undergoing in vitro fertilization. Fertil Steril, 64, 991-4. |
4 | Maltaris T, Seufert R, Fischl F et al (2007) The effect of cancer treatment on female fertility and strategies for preserving fertility. Eur J Obstet Gynecol Reprod Biol, 130, 148-55. DOI ScienceOn |
5 | Oktay K, Briggs D, Gosden RG (1997). Ontogeny of folliclestimulating hormone receptor gene expression in isolated human ovarian follicles. J Clin Endocrinol Metab, 82, 3748-51. |
6 | Oktay K, Sonmezer M, Oktem O et al (2007). Absence of Conclusive Evidence for the Safety and Efficacy of gonadotropin-releasing hormone analogue treatment in protecting against chemotherapy-induced gonadal injury. Oncologist, 12, 1055-66 DOI ScienceOn |
7 | Osborne SE, Detti L (2013). GnRH-analogues for ovarian protection in childhood cancer patients: how adult hypotheses are relevant in prepubertal females. Curr Drug Targets, 14, 856-63. DOI |
8 | Rahilly M, Carder PJ, Nafussi A et al (1991). Distribution of glutathione Stransferase isoenzymes in human ovary. J Reprod Fertil, 93, 303-11. DOI ScienceOn |
9 | Scott RT, Toner JP, Muasher SJ et al (1989). Follicle-stimulating hormone levels on cycle day 3 are predictive of in vitro fertilization outcome. Fertil Steril, 51, 651-4. |
10 | Shalev E, Leung PC (2003). Gonadotropin-releasing hormone and reproductive medicine. J Obstet Gynaecol Can, 25, 98-113. |
11 | Fox K, Scialla H, Moore H (2001). Preventing chemotherapyrelated amenorrhea using leuprolide during adjuvant chemotherapy for early stage breast cancer. Proc Am Soc Clin Oncol, 21, 98. |
12 | Del Mastro L, Catzeddu T, Boni L et al (2006). Prevention of chemotherapy induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients. Ann Oncol, 17, 74-8. |
13 | Kreuser ED, Hetzel WD, Billia DO, Thiel E (1990). Gonadal toxicity following cancer therapy in adults: significance, diagnosis, prevention and treatment. Cancer Treat Rev, 17, 169-75. DOI ScienceOn |
14 | Del Mastro L, Ceppi M, Poggio F(2013). Gonadotropin-releasing hormone analogues for the prevention of chemotherapyinduced premature ovarian failure in cancer women: Systematic review and meta-analysis of randomized trials. Cancer treatment reviews. Cancer Treat Rev, [Epub ahead of print] |
15 | Emons G, Grundker C, Gunthert AR et al (2003). GnRH antagonists in the treatment of gynaecological and breast cancers. Endocr Relat Cancer, 10, 291-9. DOI ScienceOn |
16 | Huser M, Zakova J, Smardova L et al (2012). Combination of fertility preservation strategies in young women with recently diagnosed cancer. Eur J Gynaecol Oncol, 33, 42-50. |
17 | Lamar CA, DeCherney AH (2009). Fertility preservation: state of the science and future research directions. Fertil Steril, 91, 316-9. DOI ScienceOn |
18 | Laml T, Schulz-Lobmeyr I, Obruca A, Huber J, Hartmann B (2000).Premature ovarian failure: Etiology and prospects. Gynecol Endocrinol, 14, 292-302. DOI ScienceOn |
19 | Lee SJ, Schover LR , Partridge AH et al (2006). American Society of Clinical Oncology. Recommendations on Fertility Preservation in Cancer Patients. J Clin Oncol, 24, 2917-31 DOI ScienceOn |
20 | Bonadonna G, Valagussa P (1985). Adjuvant systemic therapy for resectable breast cancer. J Clin Oncol, 3, 259-75. |
21 | Ataya K, Ramahi-Ataya A (1993). Reproductive performance of female rats treated with cyclophosphamide and/or LHRH agonist. Reprod Toxicol, 7, 229-35. DOI ScienceOn |
22 | Clowse MEB, Behera MA, Anders CK et al (2009). Ovarian preservation by GnRH agonists during chemotherapy: A Meta-Analysis. J Wom Health, 18, 311-9. DOI ScienceOn |
23 | Balkenende E, Dahhan T, Veen F, Goddijn M (2011). Comment on GnRH analogue cotreatment with chemotherapy for preservation of ovarian function. Fertil Steril, 96, 155-6 |
24 | Bedaiwy MA, Abou-Setta AM, Desai N et al (2011). Gonadotropin-releasing hormone analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy: a systematic review and meta-analysis. Fertil Steril, 95, 906-14 DOI ScienceOn |
25 | Chen H, Li J, Cui T, Hu L (2011). Adjuvant gonadotropinreleasing hormone analogues for the prevention of chemotherapy induced premature ovarian failure in premenopausal women. Cochrane Database Syst Rev, 11, 8018. |
26 | Cobleigh M (1995). Amenorrhea following adjuvant chemotherapy for breast cancer. Proc Am Soc Clin Oncol, 14, 158. |
27 | Dada T, Salha O, Allgar V, Sharma V (2001). Utero-ovarian blood flow characteristics of pituitary desensitization. Hum Reprod, 16, 1663-70. DOI ScienceOn |
![]() |